Inthera Bioscience, a Zurich, Switzerland-based biopharmaceutical company developing targeted small molecule therapies for solid tumors, closed a CHF10.5m (€9.6m) Series A financing.
The round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo Seeds and the participation of a private investor. In conjunction with the financing round, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures joined Inthera’s Board of Directors.
The company will use the funds to complete the pre-clinical development of its lead program against HPV-associated cancers and expand operations and the pipeline.
Incorporated in 2013 by Ulrich Kessler and Paramjit Arora, Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs are focused on the development of novel oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.